Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) issued its quarterly earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17), Zacks reports. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. During the same period in the prior year, the firm earned ($0.42) EPS. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% compared to the same quarter last year.

Recursion Pharmaceuticals Trading Down 2.1 %

Shares of RXRX opened at $7.51 on Friday. The company’s fifty day moving average is $7.72 and its 200 day moving average is $7.08. Recursion Pharmaceuticals has a fifty-two week low of $5.60 and a fifty-two week high of $14.12. The stock has a market capitalization of $2.93 billion, a PE ratio of -4.91 and a beta of 0.86. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp lowered their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday. Finally, Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.